Related Experiment Videos
Hepatitis C virus genotypes, hepatitis, and hepatitis C virus recurrence after liver transplantation
L S Belli1, E Silini, A Alberti
1Divisione di Medicina Generale-Epatologia CRESPI, Ospedale Niguarda Ca' Granda, Milan, Italy.
Insights
Hepatitis C virus (HCV) genotype 1b infection after liver transplant is linked to a higher risk of recurrent hepatitis and severe liver disease compared to genotype 2a.
Area of Science:
- Hepatology
- Virology
- Transplantation Immunology
Background:
- Hepatitis C virus (HCV) genotypes vary, but their impact on liver transplant outcomes remains unclear.
- Understanding genotype-specific risks is crucial for managing post-transplant hepatitis C.
Purpose of the Study:
- To assess the clinical relevance of different HCV genotypes in the liver transplant setting.
- To determine the incidence and progression of recurrent hepatitis C based on HCV genotype.
Main Methods:
- Prospective evaluation of 50 liver transplant recipients for HCV-related liver disease.
- Liver biopsies for histological grading and staging; HCV RNA detection via RT-PCR.
- HCV genotyping using primer-specific PCR; follow-up ranging from 6 to 62 months.
Main Results:
- HCV genotype 1b was most prevalent (31/50 patients), followed by genotype 2a (13/50).
- Five-year actuarial rates for recurrent hepatitis were 56% for genotype 1b vs. 33% for genotype 2a (P=.18).
- Severe fibrosis/cirrhosis rates at 5 years were 20% for genotype 1b vs. 8% for genotype 2a (P=.16).
Conclusions:
- HCV genotype 1b infection shows a trend towards more aggressive recurrent liver disease post-transplant.
- These findings suggest genotype-specific differences in the clinical course of hepatitis C after liver transplantation.
Abstract:
Several genotypes of hepatitis C virus (HCV) have been recently identified by phylogenetic analysis, but their clinical relevance in the liver transplant setting is unknown. We evaluated the incidence and course of recurrent hepatitis C after transplantation in 50 patients who underwent transplantation for HCV-related liver disease. Liver biopsy specimens were obtained when clinically indicated and at yearly intervals; hepatitis was histologically graded and staged according to standard criteria. HCV-RNA was detected by nested reverse-transcription polymerase chain reaction (RT-PCR). HCV genotyping was performed by primer specific PCR. Follow-up was 6 to 62 months. HCV genotype distribution after transplantation of our 50 patients was as follows: 31 type 1b, 13 type 2a, 3 type 1a, 1 type 3a, 1 type 1b/2a, and 1, undetermined. Actuarial rates of recurrent hepatitis and of severe fibrosis or cirrhosis 5 years after transplantation were 56% and 20%, respectively, in patients infected by type 1b and 33% (P = .18) and 8% (P = .16) in those infected by 2a. In conclusion, this study provides evidence that in patients infected by HCV type 1b there is a trend for a more aggressive recurrent liver disease.